Brief: Akeso Granted Exclusive Commercialization Rights For Ebronucimab Injection To Jumpcan Pharmaceutical
03/02/2026 14:55
Feb 3 (Reuters) - Akeso Inc 9926.HK: AKESO GRANTED EXCLUSIVE COMMERCIALIZATION RIGHTS FOR EBRONUCIMAB INJECTION TO JUMPCAN PHARMACEUTICAL TO RECEIVE RMB80 MILLION LICENSE FEE AND RMB10 MILLION MILESTONES Further company coverage: 9926.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals